Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.

Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

The oncology community has sounded the alarm over the Trump administration's 2026 budget proposal, which includes near-40% ...

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

Merus initially surged on superior interim trial data, while Bicara Therapeutics tanked. Click here to find out why BCAX ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...

CHICAGO — Daily adjuvant aspirin did not reduce disease recurrence for patients with colorectal cancer liver metastases and ...

Lurbinectedin and atezolizumab performed better than atezolizumab alone as maintenance therapy for extensive-stage small cell lung cancer.

An analysis of oral presenters at ASCO Annual Meeting revealed considerable disparities based on career stage, gender, subspecialty and geographic region.Mid- to late-career medical oncologists from ...

A budding resort outside of South Haven looks to bring a new sound of events to the lakeshore. But nearly a dozen people who ...

Dr Mariana Chavez MacGregor reports on advances from ASCO 2025, emphasizing treatment de-escalation and emerging tools like ctDNA for personalized care.